[1]贾丝雨,张乔盟,张雨馨,等.HBV相关肝细胞癌基因甲基化机制及中药干预研究的最新进展[J].现代检验医学杂志,2026,41(03):198-204.[doi:10.3969/j.issn.1671-7414.2026.03.036]
　JIA Siyu,ZHANG Qiaomeng,ZHANG Yuxin,et al.Latest Advances in Gene Methylation Mechanisms and Traditional Chinese Medicine Intervention of HBV-Associated Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2026,41(03):198-204.[doi:10.3969/j.issn.1671-7414.2026.03.036]
点击复制

HBV相关肝细胞癌基因甲基化机制及中药干预研究的最新进展()

《现代检验医学杂志》[ISSN:/CN:]

卷:
第41卷
期数:
2026年03期
页码:
198-204
栏目:
综述
出版日期:
2026-05-13

文章信息/Info

Title:
Latest Advances in Gene Methylation Mechanisms and Traditional Chinese Medicine Intervention of HBV-Associated Hepatocellular Carcinoma
文章编号:
1671-7414（2026）03-198-07
作者:
贾丝雨1，张乔盟1，张雨馨1，周嘉迪2，王战争2，冯飞雪1,2，马艳侠1，刘永刚2，王润雯1
1.陕西中医药大学医学技术学院，陕西咸阳712046;2.陕西中医药大学附属医院，陕西咸阳712000
Author(s):
JIA Siyu1，ZHANG Qiaomeng1，ZHANG Yuxin1，ZHOU Jiadi2，WANG Zhanzheng2，FENG Feixue1,2，MA Yanxia1，LIU Yonggang2，WANG Runwen1
1.College of Medical Technology, Shaanxi University of Chinese Medicine, Shaanxi Xianyang 712046, China ;2.Affiliated Hospital of Shaanxi University of Chinese Medicine, Shaanxi Xianyang 712000, China
关键词:
肝细胞癌; 乙型肝炎病毒; 表观遗传; 甲基化; 中药
分类号:
R735.7；R730.5
DOI:
10.3969/j.issn.1671-7414.2026.03.036
文献标志码:
A
摘要:
肝细胞癌（HCC）在全球癌症死亡中排名第三，传统生物标志物及影像学技术灵敏度和特异度较低，早期诊断困难是导致其高发病率和死亡率的重要原因。乙型肝炎病毒（HBV）感染是HCC发生的危险因素之一，可引发基因甲基化异常及表观遗传学改变。这种可逆的甲基化特性为探索新的生物标志物提供了新的思路与视角，有望提升HCC的早诊率并改善治疗。近年来，中药凭借其副作用低、不良反应少等独特优势，在HCC的预防和治疗中发挥重要作用，研究已发现多种针对甲基化的中药并应用于临床治疗。该综述旨在梳理大量关于HBV相关HCC甲基化机制的研究进展以及中药针对甲基化基因抗癌治疗的研究成果，以期发现新的标志物和治疗手段，提高HCC的早诊率和生存率。
Abstract:
Hepatocellular Carcinoma (HCC) ranks as the third leading cause of cancer-related deaths globally. The low sensitiv-ity and specificity of traditional biomarkers and imaging techniques, as well as the difficulty in early diagnosis, are major factors contributing to its high incidence and mortality. Hepatitis B virus (HBV) infection, causing abnormal gene methylation and epi-genetic alterations, is one of the risk factors for HCC. The reversible methylation characteristic offers new insights and perspec-tives for exploring new biomarkers, with the potential to increase early diagnosis rates and improve the treatment outcomes for HCC. In recent years, traditional Chinese medicine has played an important role in the prevention and treatment of HCC due to its unique advantages of low side effects and few adverse reactions. Studies have discovered a variety of traditional Chinese med-icine formulations targeting methylation that have been applied in clinical treatment. This review aims to summarize the latest re-search progress on the methylation mechanisms of HBV-associated HCC and the findings of traditional Chinese medicine-based anti-cancer treatments targeting methylated genes, with the expectation of discovering new markers and therapeutic approaches to improve the early diagnosis rate and survival rate of HCC.

参考文献/References:

[1] BRAY F, LAVERSANNE M, SUNG H, et al. Glob-al cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA: a Cancer Journal for Clinicians, 2024, 74(3):229-263.
[2] 王可欣,纪冬.乙型肝炎病毒与肝细胞癌关系研究进展[J].传染病信息,2022,35(2):166-171. WANG K X, JI D. Advances on the relationship between hepatitis B virus and hepatocellular carcinoma [J]. Infec-tious Disease Information, 2022, 35(2): 166-171.
[3] SHEN C, JIANG X, LI M, et al. Hepatitis virus and hepatocellular carcinoma: recent advances[J]. Cancers, 2023, 15(2): 533.
[4] CHEN Q L, YAN Q, FENG K L, et al. Using integrated bioinformatics analysis to identify abnormally meth-ylated differentially expressed genes in hepatocellular carcinoma [J]. International Journal of General Medi-cine, 2021, 14: 805-823.
[5] GON?ALVES E, GON?ALVES-REIS M, PEREI-RA-LEAL J B, et al. DNA methylation fingerprint of hepatocellular carcinoma from tissue and liquid biop-sies [J]. Scientific Reports, 2022, 12:11512.
[6] 赵海潮, 高强. 2022年度肝癌研究及诊疗新进展[J].中国癌症杂志,2023,33(4):315-326 ZHAO H C, GAO Q. Progress in research, diagnosis,and treatment of hepatocellular carcinoma in 2022[J]. China Oncology, 2023, 33(4): 315-326.
[7] ZHU D Q, LI A W, LV Y, et al. Traditional Chinese medicine: a class of potentially reliable epigenetic drugs [J]. Frontiers in Pharmacology, 2022, 13:907031.
[8] 陈映均,刘同刚. HBV相关肝细胞癌抑癌基因甲基化异常及机制的研究进展[J].中国医学创新,2023, 20(23):168-175. CHEN Y J, LIU T G. Research progress on the abnor-mal methylation and mechanism of tumor suppressor genes in HBV-associated hepatocellular carcinoma[J]. Medical Innovation of China, 2023, 20(23): 168-175.
[9] 韩家鑫,宓余强,徐亮. 肝细胞癌早期筛查和诊断的研究进展[J].临床肝胆病杂志,2023,39(6):1468-1475. HAN J X, MI Y Q, XU L. Research advances in early screening and diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(6): 1468-1475.
[10] CHEN J T, NIU C, YANG N, et al. Biomarker dis-covery and application-an opportunity to resolve the challenge of liver cancer diagnosis and treatment[J]. Pharmacological Research, 2023, 189: 106674.
[11] OMAR A. Role of epigenetics alternations in carcinogen-esis[J]. Journal of Carcinogenesis, 2023,22(1): 11-19.
[12] YU X Y, ZHAO H, WANG R Q, et al. Cancer epigenetics:from laboratory studies and clinical trials to precision medicine [J]. Cell Death Discovery, 2024, 10: 28.
[13] 中国抗癌协会肿瘤标志专业委员会.肿瘤DNA甲基化标志物检测及临床应用专家共识(2024版)[J].中国癌症防治杂志, 2024, 16(2):129-142. Tumor Marker Committee of Chinese Anti-Cancer As-sociation. Expert consensus on detection and clinical application of tumor DNA methylation markers (Version 2024)[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(2): 129-142.
[14] CHEN X Y, SONG X, ZHENG X R, et al. Nucleolar NOL9 regulated by DNA methylation promotes hepa-tocellular carcinoma growth through activation of Wnt/β-catenin signaling pathway[J]. Cell Death & Disease, 2025, 16: 100.
[15] 严倩. 基于网络药理学和全基因组甲基化测序探讨肝积方干预 HBV 相关肝细胞癌的分子机制[D].广州:广州中医药大学,2021. YAN Q. Based on network pharmacology and whole-genome methylation sequencing to explore the mo-lecular mechanism of Ganji fang’s intervention in HBV-related hepatocellular carcinoma [D]. Guangzhou:Guangzhou University of Chinese Medicine,2021.
[16] EL-SHAARAWY F, ABO ELAZM M M, MOHAMED R H, et al. Relation of the methylation state of RUNX3 and p16 gene promoters with hepatocellular carcinoma in Egyptian patients[J]. Egyptian Journal of Medical Human Genetics, 2022, 23:48.
[17] KIM M, DELGADO E, KO S. DNA methylation in cell plasticity and malignant transformation in liver diseas-es[J]. Pharmacology & Therapeutics, 2022, 241: 108334.
[18] CUI J, LI G Q, YIN J, et al. GSTP1 and cancer: expres-sion, methylation, polymorphisms and signaling (Re-view) [J]. International Journal of Oncology, 2020, 56:867-878.
[19] CHAN Y T, ZHANG C, WU J Y, et al. Biomarkers for diagnosis and therapeutic options in hepatocellular car-cinoma [J]. Molecular Cancer, 2024, 23:189.
[20] ZHANG Y Q, CAO W H, WANG S Y, et al. Epigenetic modification of hepatitis B virus infection and related hepatocellular carcinoma [J]. Virulence, 2024,15(1):2421231.
[21] YAN Y C, HUANG P B, MAO K, et al. Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carci-noma progression [J]. Oncogene, 2020, 40(1): 28-45.
[22] 胡斐, 陈丽, 毕明瑜, 等. RASSF1A基因及其在结直肠癌中的研究进展[J]. 生命科学, 2020, 32(2): 143-148. HU F, CHEN L, BI M Y, et al. Role of the Ras-association domain family 1 isoform A in colorectal cancer [J]. Chi-nese Bulletin of Life Sciences, 2020, 32(2): 143-148.
[23] XU G, ZHOU X X, XING J L, et al. Identification of RASSF1A promoter hypermethylation as a biomarker for hepatocellular carcinoma [J].Cancer Cell Interna-tional, 2020, 20(1): 547.
[24] LI J W, CHENG X Z, HUANG D G, et al. Six2 reg-ulates the malignant progression and 5-FU resistance of hepatocellular carcinoma through the PI3K/AKT/mTOR pathway and DNMT1/E-cadherin methylation mechanism [J]. Neoplasma, 2024, 71(5): 451-462.
[25] KANAI Y. Molecular pathological approach to cancer epigenomics and its clinical application [J]. Pathology International, 2024, 74(4): 167-186.
[26] BAO Q L, ZENG Y F, LOU Q Z, et al. Clinical signifi-cance of RNA methylation in hepatocellular carcinoma [J]. Cell Communication and Signaling, 2024, 22:204.
[27] REN W J, YUAN Y X, LI Y W, et al. The function and clinical implication of YTHDF1 in the human system development and cancer [J]. Biomarker Research, 2023, 11(1): 5.
[28] XU R Y, DING Z, ZHAO Q, et al. An alternatively spliced variant of METTL3 mediates tumor suppression in hepa-tocellular carcinoma [J]. Genes, 2022, 13(4): 669.
[29] LI R, LIU X C, DENG K Y, et al. M7G methylated core genes (METTL1 and WDR4) and associated RNA risk sig-natures are associated with prognosis and immune escape in HCC [J]. BMC Medical Genomics, 2023, 16(1): 179.
[30] SU L, BU J W, YU J H, et al. Comprehensive review and updated analysis of DNA methylation in hepatocel-lular carcinoma: from basic research to clinical appli-cation [J]. Clinical and Translational Medicine, 2024, 14(11): e70066.
[31] YANG Y, YAN Y, YIN J X, et al. O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carci-noma progression in an N6-methyladenosine-dependent manner[J]. Signal Transduction and Targeted Therapy, 2023, 8(1): 63.
[32] 雷雪,张俐佳,尹新宇,等.中医中药治疗结直肠癌的研究进展[J].临床医学进展,2024, 14(3):1360-1368. LEI X, ZHANG L J, YIN X Y, et al. Research progress of traditional Chinese medicine in the treatment of col-orectal cancer[J]. Advances in Clinical Medicine, 2024,14(3):1360-1368.
[33] 陈杨柳,李媛,官志杰.中医药治疗原发性肝癌的研究进展[J].基层中医药,2024,3(12):112-116. CHEN Y L, LI Y, GUAN Z J. Progress on treating prima-ry liver cancer by traditional Chinese medicine [J].Basic Traditional Chinese Medicine, 2024, 3(12): 112-116.
[34] 肖琨珉,朱世杰,李可歆,等. 近10年中医药治疗肝癌研究的知识图谱分析[J].世界中西医结合杂志, 2022,17(2):236-242,248. XIAO K M, ZHU S J, LI K X, et al. Knowledge-map analysis of traditional Chinese medicine in the treat-ment of liver cancer in the past decade [J]. World Jour-nal of Integrated Traditional and Western Medicine, 2022, 17(2): 236-242, 248.
[35] 邱文亮,孙倩倩,邱冰.中药及其活性成分在肝癌治疗中的作用机制研究进展[J].中医药信息,2022, 39(5):79-84. QIU W L, SUN Q Q, QIU B. Action mechanism prog-ress of Chinese medicinal and its active ingredients in treatment of hepatic carcinoma [J]. Information on Tra-ditional Chinese Medicine, 2022, 39(5): 79-84.
[36] 丁玲玲.中医药改善中晚期原发性肝癌生存预后的研究进展[J].中医学,2023, 12(7):1719-1724. DING L L. Research progress of traditional Chinese medicine in improving survival and prognosis of ad-vanced primary liver cancer [J]. Traditional Chinese Medicine, 2023, 12(7):1719-1724.
[37] 张景媛.基于生物信息学的茵陈蒿汤和茵栀黄颗粒抑制肝脏炎癌转化机制研究[D].北京:北京中医药大学,2022. ZHANG J Y. Study on the inhibitory mechanism of Yinchenhao decoction and Yinzhihuang granules on hepatitis carcinoma transformation based on bioin-formatics [D]. Beijing: Beijing University of Chinese Medicine, 2022.
[38] 齐婧姝,平大冰,孙鑫,等. 基于网络药理学探讨扶正化瘀方治疗肝癌的作用机制[J].临床肝胆病杂志, 2021,37(10):2338-2342. QI J S, PING D B, SUN X, et al. Mechanism of action of Fuzheng Huayu prescription in treatment of liver cancer based on network pharmacology [J]. Journal of Clinical Hepatology, 2021, 37(10): 2338-2342.
[39] 罗黎明,刘志勇. DNA甲基化在癌症预防与治疗中的研究进展[J].江西中医药,2022,53(11):76-80. LUO L M, LIU Z Y. Advances in research on DNA methylation in cancer prevention and treatment [J]. Jiangxi Journal of Traditional Chinese Medicine, 2022, 53(11): 76-80.
[40] 赵卓,王智民,刘子玉,等. N6-甲基腺嘌呤甲基化:中医药防治疾病的新兴靶点[J].中华中医药学刊, 2024,42(5):77-81,278. ZHAO Z, WANG Z M, LIU Z Y, et al. N6-methylad-enosine methylation: a new target for prevention and treatment of diseases by traditional Chinese medicine [J]. Chinese Archives of Traditional Chinese Medicine, 2024, 42(5): 77-81, 278.
[41] 韩笑,王梦斐,蒲位凌,等.中药活性成分通过调节m6A甲基化修饰抗肿瘤的研究进展[J].中草药,2024,55(6):2123-2130. HAN X, WANG M F, PU W L, et al. Advances in an-ti-cancer research of active ingredients of traditional Chinese medicine through regulation of m6A methyl-ation modification[J]. Chinese Traditional and Herbal Drugs,2024, 55(6): 2123-2130.
[42] JIANG H P, YAO Q Q, AN Y B, et al. Baicalin suppress-es the progression of Type 2 diabetes-induced liver tu-mor through regulating METTL3/m6A/HKDC1 axis and downstream p-JAK2/STAT1/clevaged Capase3 pathway [J]. Phytomedicine, 2021, 94: 153823.
[43] ZHANG L L, KE W W, ZHAO X X, et al. Resina dra-conis extract exerts anti-HCC effects through MET-TL3-m6A-survivin axis[J]. Phytotherapy Research, 2022, 36(6): 2542-2557.
[44] 李毅.白藜芦醇对肝脏脂代谢和能量代谢及RNA甲基化修饰影响的研究[D].南京: 南京农业大学, 2021.LI Y. Study of resveratrol on lived lipid metabolism, en-ergy metabolism and RNA methylation modification[D]. Nanjing: Nanjing Agricultural University, 2021.
[45] WANG L, ZHANG C Y, GUO Y, et al. Blocking of JB6 cell transformation by tanshinone IIA: epigenetic re-activation of Nrf2 antioxidative stress pathway[J]. The AAPS Journal, 2014, 16(6): 1214-1225.
[46] 范金花.黄连碱通过促进IGF2BP1泛素化抑制肝细胞癌增殖和转移的机制研究[D].重庆:西南大学,2023. FAN J H. The mechanism of coptisine inhibiting the pro-liferation and metastasis of hepatocellular carcinoma by promoting the ubiquitination of IGF2BP1[D]. Chongq-ing: Southwest University, 2023.DUAN X C, ZHOU T T, LIU M Z, et al. Analysis of document control and improvement in the quality man-agement system of medical laboratories[J]. China Health Industry, 2019, 16(19): 43-44.

相似文献/References:

[1]李步荣,张彤,李丽华,等.CHB患者HBV基因型及耐药突变基因联合检测临床研究[J].现代检验医学杂志,2015,30(05):40.[doi:10.3969/j.issn.1671-7414.2015.05.012]
　LI Bu-rong,ZHANG Tong,LI Li-hua,et al.Clinical Study of Combined Detection about Hepatitis B Virus Genotypes and Drug Resistant Mutation Genes in Patients with Chronic Hepatitis B[J].Journal of Modern Laboratory Medicine,2015,30(03):40.[doi:10.3969/j.issn.1671-7414.2015.05.012]
[2]景媛媛,李锦,段勇,等.青年献血人群HBV/OBI感染者血清中IL-10表达水平的分析[J].现代检验医学杂志,2015,30(05):107.[doi:10.3969/j.issn.1671-7414.2015.05.033]
　JING Yuan-yuan,LI Jin,DUAN Yong,et al.Analysis of IL-10 in Serum of Blood Donors with OBI/HBV Infection among Young Adults[J].Journal of Modern Laboratory Medicine,2015,30(03):107.[doi:10.3969/j.issn.1671-7414.2015.05.033]
[3]邓旭,王晓亮.肝细胞癌患者血清趋化因子CXCR12和SA的表达及临床意义[J].现代检验医学杂志,2015,30(06):49.[doi:10.3969/j.issn.1671-7414.2015.06.014]
　DENG Xu,WANG Xiao-liang.Expression and Clinical Significance of Serum CXCR12 and SA in Patients with Hepatocarcinoma[J].Journal of Modern Laboratory Medicine,2015,30(03):49.[doi:10.3969/j.issn.1671-7414.2015.06.014]
[4]谢小娟,李小侠,李芒会,等.孕产妇及其新生儿的HBV检测结果相关性分析[J].现代检验医学杂志,2015,30(02):80.[doi:10.3969/j.issn.1671-7414.2015.02.025]
　XIE Xiao-juan,LI Xiao-xia,LI Mang-hui,et al.Correlation Analysis of Maternal and Neonatal HBV Test Results[J].Journal of Modern Laboratory Medicine,2015,30(03):80.[doi:10.3969/j.issn.1671-7414.2015.02.025]
[5]何紫琪,李从荣,尹 路.乙型肝炎病毒逆转录酶基因突变的临床意义[J].现代检验医学杂志,2016,31(04):83.[doi:10.3969/j.issn.16717-414.2016.04.022]
　HE Zi-qi,LI Cong-rong,YIN Lu.Clinical Significance of Reverse Transcriptase Gene Mutations in the Hepatitis B Virus[J].Journal of Modern Laboratory Medicine,2016,31(03):83.[doi:10.3969/j.issn.16717-414.2016.04.022]
[6]王海宁,李万顺,孙巨军.乙肝病毒血清标志物、外周血T淋巴细胞与HBV-DNA的相关性分析[J].现代检验医学杂志,2016,31(04):113.[doi:10.3969/j.issn.16717-414.2016.04.032]
　WANG Hai-ning,LI Wan-shun,SUN Ju-jun.Correlation Study on Serum Markers of Hepatitis B Virus and Peripheral T Lymphocytes as Well as HBV-DNA in Patients with Hepatitis B[J].Journal of Modern Laboratory Medicine,2016,31(03):113.[doi:10.3969/j.issn.16717-414.2016.04.032]
[7]毛丽萍,何义民,韩 刚,等.血浆Dickkopf同源物1检测对肝细胞癌的诊断价值[J].现代检验医学杂志,2016,31(05):62.[doi:10.3969/j.issn.1671-7414.2016.05.016]
　MAO Li-ping,HE Yi-min,HAN Gang,et al.Diagnosis Value of Detecting Plasma Dickkopf-1 Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2016,31(03):62.[doi:10.3969/j.issn.1671-7414.2016.05.016]
[8]阮瑞杨,陈修荣,赵世元.抗EZH2自身抗体IgG在肝癌患者血清中的表达及意义[J].现代检验医学杂志,2017,32(02):72.[doi:10.3969/j.issn.1671-7414.2017.02.019]
　RUAN Rui-yang,CHEN Xiu-rong,ZHAO Shi-yuan.Expression and Significance of Anti EZH2 Autoantibodies IgG in Hepatocellular Carcinoma Patient's Serum Samples[J].Journal of Modern Laboratory Medicine,2017,32(03):72.[doi:10.3969/j.issn.1671-7414.2017.02.019]
[9]解 娟,刘文康,李 玲,等.化学发光分析法定量检测住院患者HBV血清标志物及临床意义[J].现代检验医学杂志,2017,32(03):40.[doi:10.3969/j.issn.1671-7414.2017.03.011]
　XIE Juan,LIU Wen-kang,LI Ling,et al.Clinical Implication of HBV Serum Markers Detected with Chemiluminescent Immunoassay in Inpatients of Xi’an Area[J].Journal of Modern Laboratory Medicine,2017,32(03):40.[doi:10.3969/j.issn.1671-7414.2017.03.011]
[10]徐少华,赵 静,朱 琳,等.HBeAg阳性慢性乙型肝炎患者大量输血后其血清标志物变化研究[J].现代检验医学杂志,2017,32(06):147.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　XU Shao-hua,ZHAO Jing,ZHU Lin,et al.Changes of Serum Markers in Patients with HBeAg Positive Chronic Hepatitis B after Massive Blood Transfusion[J].Journal of Modern Laboratory Medicine,2017,32(03):147.[doi:10.3969/j.issn.1671-7414.2017.06.001]

备注/Memo

备注/Memo:
基金项目： 陕西省重点研发计划（No:2024SF-YBXM-528）；咸阳市重点研发计划(No:L2022ZDYFSF002)；陕西中医药大学2024年度研究生质量提升工程专项项目(KCJ202407)。
作者简介：贾丝雨（2002-），女，在读硕士，研究方向：临床检验诊断学，E-mail:1944347781@qq.com。
通讯作者：马艳侠（1975-），女，主任技师，研究方向：生化检验，E-mail:zhmazhch81763@163.com。
更新日期/Last Update: 2026-05-15